Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
08/18 CYTOKINETICS : Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of T..
08/17 CYTOKINETICS INC : Other Events (form 8-K)
08/17 Cytokinetics Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of ..
08/04 CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
07/28 CYTOKINETICS : reports 2Q loss
07/28 CYTOKINETICS INC : Results of Operations and Financial Condition, Financial Stat..
07/28 Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results
07/27 Cytokinetics and The ALS Association Renew Partnership to Advance the Fight A..
07/27 CYTOKINETICS INC : Entry into a Material Definitive Agreement (form 8-K)
07/27 Cytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion ..
More news
Sector news : Bio Therapeutic Drugs
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2016 30,1 M
EBIT 2016 -48,9 M
Net income 2016 -51,2 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 16,1x
Capi. / Sales 2017 14,9x
Capitalization 486 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,0 $
Spread / Average Target 64%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Sharon A. Barbari Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.486
AMGEN, INC.5.94%128 696
GILEAD SCIENCES, INC.-21.17%105 269
CELGENE CORPORATION-9.16%84 325
REGENERON PHARMACEUTIC..-25.77%42 431
VERTEX PHARMACEUTICALS..-22.84%24 057
More Results